Austria

Cebina

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

AUSTRIA Austria

Post An Enquiry

Virtual Booth

Arab Health 2021

Participation Not Confirmed

Update your events

CEBINA Reports Positive Findings on the Potency of Azelastine, a Widely Used Anti-Histamine, as Anti-Covid-19 Approach

Lead Product(s): Azelastine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 17, 2020

Details:

The potent anti-SARS-CoV-2 activity of azelastine formulated in a nasal spray was demonstrated in an experimental reconstituted human nasal tissue model and was evident at a lower dose than present in commercially available products.

Marinomed Biotech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

AUSTRIA Austria

Post An Enquiry

Virtual Booth

Arab Health 2021

Participation Not Confirmed

Update your events

Marinomed Biotech AG Announces that Carragelose® has the Potential to Reduce the Risk of an Infection with SARS-CoV-2

Lead Product(s): Carrageenan API

Therapeutic Area: Infections and Infectious Diseases Product Name: Carragelose

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 16, 2020

Details:

Data from Marinomed’s cell-culture study confirm that Carragelose® works in a dose-dependent manner to strongly reduce the infection of cells from the SARS-CoV-2 virus.

Themis Bioscience

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

AUSTRIA Austria

Post An Enquiry

Virtual Booth

Arab Health 2021

Participation Not Confirmed

Update your events

Merck Completes Acquisition of Themis

Lead Product(s): SARS-CoV-2 vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Vaccine

Partner/Sponsor/Collaborator: Merck & Co. Inc.

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition June 19, 2020

Details:

An initial focus of this agreement is acceleration of the development of a measles vector-based SARS-CoV-2 vaccine candidate. This candidate is currently in pre-clinical development, and clinical studies are planned to start later in 2020.